A phase 1b/2 study to evaluate the safety and efficacy of TTI-101 as monotherapy and in combination in advanced hepatocellular carcinoma.

Category Primary study
JournalJ. Clin. Oncol.
Year 2024
This article has no abstract
Epistemonikos ID: de6cb4b03232f8549751e6c05a58ec76bd59f23f
First added on: Jan 10, 2026